- Home
- DXR vs SCYX Comparison
DXR vs SCYX Comparison
Compare DXR & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | SCYX |
|---|---|---|
| Founded | 1970 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.0M | 60.4M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DXR | SCYX |
|---|---|---|
| Price | $10.02 | $3.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 2.2K | ★ 122.5K |
| Earning Date | 02-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 61.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,446,345.00 | $257,000.00 |
| Revenue This Year | $44,935.22 | N/A |
| Revenue Next Year | $74.79 | $608.78 |
| P/E Ratio | $33.83 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.56 | $0.57 |
| 52 Week High | $14.76 | $5.62 |
Technical Indicators
Market Signals| Indicator | DXR | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 47.25 | 58.98 |
| Support Level | $9.76 | $0.67 |
| Resistance Level | $11.44 | $5.62 |
| Average True Range (ATR) | 0.44 | 0.28 |
| MACD | 0.03 | -0.16 |
| Stochastic Oscillator | 43.17 | 7.08 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.